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Background: Dentoalveolar surgery is a predisposing factor for medication related osteonecrosis of the jaw 
(MRONJ). The aim of our study was to evaluate the described surgical procedures to prevent the development of 
MRONJ after dentoalveolar surgery in patients receiving bisphosphonates.
Material and Methods: In this retrospective study, sixty-three dentoalveolar surgeries were performed on 44 pa-
tients taking bisphosphonate in accordance with the treatment procedures we described. The following procedures 
were applied to patients 1) use of antibiotics 2) performed dentoalveolar surgical procedures 3) fill the socket with 
leukocyte- and platelet-rich fibrin (L-PRF) 4) post-operative application of low level laser therapy through Nd: 
YAG laser 5) sutures were removed on post-op 14th day 6) long-term results were evaluated.
Results: Healing of all patients was uneventful. Complete mucosal healing was achieved in all patients at 1 month. 
There is no failure was observed in long-term follow-up.
Conclusions: Because of the pathophysiology of MRONJ is not fully understood and has many risk factors, defini-
tive protocols on prevention and treatment have not been established yet. Personal risk assessment is required for 
the prevention and treatment of MRONJ. The described surgical protocol may be considered to reduce the risk of 
developing MRONJ after dentoalveolar surgery due to its high success rate.





Bisphosphonates (BPs) are the most commonly used an-
tiresorptive drugs to prevent skeletal complications of 
many diseases (1). It is used to reduce serious complica-
tions such as hypercalcemia and pathological fractures, 
as well as to improve the quality of life and reduce pain 
complaints of cancer patients with bone metastases (2). 
One of the most important side effects of BPs is that it 
causes osteonecrosis in the jaw bones. Increased cases 
of osteonecrosis localized in the jaw bones related to 
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BPs and antiresorptive drugs, negative impact on quality 
of life and increased morbidity led researchers to defi-
ne early MRONJ and to investigate effective treatment 
modality. Although many studies have been conducted 
on the mechanism of action of bisphosphonates, its pa-
thophysiology remains unclear. Bisphosphonates accu-
mulate highly in bones and adjacent soft tissues with 
high turnover rates. Therefore, it is thought that if muco-
sal integrity is deteriorated, endothelial cell prophylaxis 
and wound healing delay and secondary infections occur 
in exposed mandible and maxilla, and later become os-
teonecrosis (3). 
Several factors such as therapeutic indication, drug type 
and duration, local, demographic, systemic and genetic 
factors have been mentioned in determining the inci-
dence of MRONJ (4). Local etiologic factors that are 
effective in the development of MRONJ are defined as 
dentoalveolar surgical procedures, anatomical factors, 
prosthesis and associated local oral inflammatory disea-
ses. A large review by Filleul et al. (5) concluded that 
tooth extraction was the main triggering factor in 67% of 
MRONJ cases. Tooth extraction alone is a predisposing 
factor in MRONJ formation between 52% and 61% (6). 
The incidence of osteonecrosis after tooth extraction is 
reported to be 0.5% in patients using oral BPs, whereas 
it is reported to be between 1.6% and 14.8% in patients 
using BPs intravenously (7). These studies show that 
tooth extraction is an important risk factor for MRONJ 
formation. Therefore, various procedures have been de-
termined to prevent the occurrence of osteonecrosis after 
tooth extraction. Studies include methods such as drug 
discontinuation, improved oral hygiene, antibiotic and 
mouthwash treatment, atraumatic extraction, primary 
closure of the extraction socket, laser biostimulation and 
use of autologous platelet concentrates (8,9).
The aim of our study was to evaluate the described sur-
gical procedures to prevent the development of MRONJ 
after dentoalveolar surgery in patients receiving bis-
phosphonate therapy. 
Material and Methods
This retrospective study included 44 patients (32 fema-
les, 12 males) who received bisphosphonate and antire-
sorptive drug therapy and required dentoalveolar surgery 
between 2017 May-2019 May. The study was approved 
by the ethical committee of our university (Katip Çelebi 
University Non-Interventional Clinical Studies Institu-
tional Review Board, Türkiye, No:311). All authors read 
the Helsinki Declaration and followed the guidelines in 
the study. Informed consent was obtained from all par-
ticipants.
The study included patients who were received bis-
phosphonates for osteoporosis or oncologic purposes 
requiring dentoalveolar surgery. Patients with a history 
of radiotherapy, a history of metastasis localized to the 
jawbone and with MRONJ of the extraction site were 
excluded from the study.
-Procedure
The following procedures were applied to patients who 
referred to our department for dentoalveolar surgery.
1) Demographic data, systemic diseases, history of bis-
phosphonate treatment (type of drug, route of use, dura-
tion of use), smoking habit, diabetes, steroid use were 
recorded at the first visit.
2) Clinical and radiological evaluation were performed 
to confirm the absence of MRONJ.
3) Patients continued to take medication.
4) 1000 mg of amoxicillin / clavulanic acid, 500 mg of 
metronidazole and 0.12% chlorhexidine digluconate 
mouthwash were prescribed for use 3 days before sur-
gery and for 2 weeks post-op.
5) Surgical procedures were performed under local 
anesthesia (2 ml of 4% articaine hydrochloride with 1: 
200,000 epinephrine). Intraligamental and intrapapillary 
anesthesia was not applied due not to prevent the reco-
very.
6) Only the sulcular incision was used in the extraction 
of the teeth with mucosal retention.
7) After the tooth extraction, the sharp bone edges were 
rounded with burs.
8) After the extraction, venous blood obtained from the 
patient’s peripheral blood was centrifuged at 3000 rpm 
for 10 minutes in 10 ml tubes without anticoagulant and 
obtained L-PRF placed into the extraction socket by fi-
gure-of-eight sutures. No releasing vertical incisions or 
mucoperiosteal incisions were made for the primary clo-
sure.
9) Nd: YAG laser (Fotona-Slovenia) was used for biosti-
mulation (wavelenght 1064 nm, power 1.25 W, frequen-
cy 15Hz, fiere 320 μmin diameter) on post-operative 
Day 2, 5, 7, 10, 14, 21 and 28 defocalised at 1-2 mm 
from the tissue for 1 min repeated 5 times.
10) Sutures were removed on post-op 14th day.
11) Patients using prosthesis discontinued to use their 
prosthesis for 3 months and then used with soft lining 
material.
12) Patients were examined clinically and radiologically 
at post op 1, 3 and 6 months. Figure 1 showed the surgi-
cal procedures for one of the patients.
The results were evaluated for wound healing. Treatment 
was considered successful when complete mucosal hea-
ling was achieved in the surgical field at the 1st and 3rd 
month controls without fistula or exposed bone symp-
toms. Data were collected retrospectively from patient 
records and surgical documents. For statistical analysis, 
group means and standard deviations were calculated for 
each variable ( age, gender, indication for BP, BP treat-
ment duration and interval, BP type, route of drug  admi-
nistraiton,extraction site, treatment outcome and time of 
follow-up)  by use of SPSS 21.0 (Statistical Package for 
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the Social Sciences, Chicago, IL, USA). Chi-square test 
was used to calculate categorical variables and Student-t 
test was used to calculate quantitative variables. All data 
were evaluated at a significance level of p< 0.05.
Results
A total of 44 patients were included to the study. The 
subject group consisted of 32 females and 12 males and 
a mean age of  66.3. 44 patients underwent 63 dentoal-
veolar surgeries in accordance with the treatment pro-
cedures we described (Table 1). 21 of the patients were 
on medication for underlying malignant disease (14 pa-
tients had breast cancer, 6 patients had prostate cancer 
and 1 patient has nasopharynx cancer) and 23 patients 
were using medication for osteoporosis. 18 of the pa-
tients were on zoledronate, 8 patients were on ibandro-
nate and 18 patients using alendronate. Mean duration 
of drug use via IV route: 44.6 months (25-108 months) 
and via oral route: 36.3 months (18-96 months). 23 of 
Fig. 1: In the patient who has been using zoledronate for 6 years due to prostate cancer, upper right first premolar tooth with destructive tooth 
decay involving the roots was extracted. The prepared Leukocyte and platelet-rich fibrin (L-PRF) plug was laid directly over the bone to fill 
the socket. The wound edges were sutured with figure-of-eight sutures. No releasing vertical incisions or mucoperiosteal incisions were made 
for the primary closure. Complete mucosal healing was achieved at 1 month.
Dentoalveolar Surgery Upper Jaw Mandible
A 2° to 3° grade mobility tooth extractions 18 33
Semi impacted third molars - 4
Residual roots 2 1
Destructive tooth decay involving the roots 3 2
Table 1: Dentoalveolar procedures performed in a group of patients.
the dentoalveolar surgical sites were in the maxilla and 
40 were in the mandible (Table 2). The response to treat-
ment of each patient was recorded by regular controls. 
Healing of all patients was uneventful. Complete muco-
sal healing was achieved in all patients at 1 month (Fig. 
1). The mean follow-up was 14.2 months (6-28 months). 
There was no significant difference between the each va-
riable (age, gender, indication for BP, BP treatment du-
ration and interval, BP type, extraction site) and in terms 
of healing time (p> 0.05).
Discussion
BPs use increases day by day in the treatment of os-
teoporosis and slows down the resorption process in 
the bone. It is also used effectively in the treatment of 
multiple myeloma and metastatic bone tumors to im-
prove the quality of life of the patient (10). However, 
the most serious side effect of these drugs is the risk of 
causing osteonecrosis, especially in the jaws (11). There 
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Sex
   Male 12 cases
   Female 32 cases
Mean age (years) 66.3 ±10.61
Systemic Disease
   Breast Cancer 14 cases
   Prostate Cancer 6 cases
   Nasopharynx Cancer 1 case
   Osteoporosis 23 cases
Drug Type
   Zoledronate 18 cases
   Ibandronate 8 cases
   Alendronate 18 cases
Route of Drug Administraiton
    Intravenous 20 cases
    Oral 24 cases
Duration of drug therapy
    Intravenous 44 months (25-108 months)
    Oral 36 months (18-96 months)
Extraction site
   Upper Jaw 23 cases
   Mandible 40 cases
Other risk factors
   Smoking habit 7 cases   
   Steroids 2 cases
   Diabetes 9 cases
Table 2: Clinical characteristics of patients included in the study.
is evidence to support that the incidence of MRONJ has 
been reduced by half in patients with preventive precau-
tions before starting BP treatment (12). However, due to 
the lack of evidence-based studies in patients receiving 
bisphosphonate or antiresorptive therapy, a protocol to 
prevent MRONJ has not been established and is limited 
to the clinical experience of the researchers alone (13). 
Therefore, the aim of this study was to define a proce-
dure to reduce the risk of MRONJ and stimulate healing 
after tooth extraction and to evaluate its effectiveness. 
In the literature, drug discontinuation before surgical 
procedures are discussed. Drug discontinuation may 
be a procedure to reduce the risk of MRONJ in patients 
with osteoporosis who do not require an urgent tooth 
extraction and can be discontinued with bisphosphonate 
therapy (14). In contrast, Hasegawa et al. (15) reported 
in a multicenter study that short-term drug withdrawal 
had no significant effect on the incidence of MRONJ. In 
our study, drug discontinuation was not applied due to 
the systemic diseases of patients and the long half-life of 
bisphosphonates.
Local infections alter the pH within the lesion, which is 
thought to be an important factor in the pathogenesis of 
jawbone osteonecrosis (16). Teeth that are indicated for 
extraction due to residual roots, periodontitis, pericoro-
nitis, excessive caries are a local factor of infection and a 
risk factor for MRONJ (17). In this study, local infection 
site were eliminated by extracting teeth or roots. Anti-
biotics and antiseptic mouthwashes were used for pre op 
3 days and post op 2 weeks before sutures were taken 
to prevent bacterial contamination of the bone and the 
surgical site and the underlying bone. 
Sharp bone edges in the surgical site increase the risk of 
secondary perforation; this is supported by the finding 
that MRONJ develops in the areas where mucosal thin-
ning occurs (18). Therefore, all sharp bone edges in the 
surgical site should be eliminated to minimize the risk 
of secondary perforation (8). Thin oral mucosa on the 
sharp bone edge can be damaged by traumatic irritation. 
For this reason, the sharp edges of the bones were roun-
ded in our patients and it was recommended that patients 
who use prosthesis should not use their prosthesis for 3 
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months. Three months later, the prostheses were lined 
and the patients were followed up.
The mechanism of action of BPs in the extraction soc-
ket has been described as decreasing oral epithelial cell 
migration, increasing apoptosis, preventing oral mucosal 
wound healing and inhibition of osteclastic activity (19). 
Hikita et al. (20) investigated the effects of bisphospho-
nates on post-extraction socket healing in rats. Histologi-
cal and morphometric data showed that inhibition of os-
teoclast activity delayed post-extraction alveolar healing 
in rats injected with bisphosphonate compared to control 
group rats. The first 7 days after dentoalveolar surgery 
appear to be the most critical period for the onset of in-
flammatory processes that prevent healing and induce os-
teonecrosis (21). Autologous platelet consantrates (APCs) 
contain many growth factors and immune system com-
ponents to support the healing process. Several clinical 
studies have reported the possible benefits of APCs in the 
prevention and treatment of MRONJ (22). Scoletta et al. 
(23) and Mazzetto et al. (24) reported that they prevented 
the formation of osteonecrosis by placing plasma rich in 
growth factors (PRGF) in the socket and Asaka et al. (25) 
reported that they prevented the formation of osteonecro-
sis by placing PRF. PRF is a second generation platelet 
concentrate that regulates inflammation and stimulates 
chemotactic factors involved in the immune response. 
Unlike platelet rich plasma (PRP) and PRGF, it is a com-
pletely autogenous biomaterial obtained without adding 
any external substances (26). 
In this study, we applied L-PRF to the extraction sockets 
simultaneously with tooth extraction in patients at risk 
of MRONJ. Osteonecrosis was not encountered in any 
of our patients during short and long term follow-up. 
Previous studies have highlighted the importance of pri-
mary closure of extraction sockets. Vertical incisions or 
mucoperiosteal incisions were not performed to prevent 
pain and edema. The wound edges were sutured with 
figure-of-eight sutures.
The effects of low-level laser therapy (LLLT) on wound 
healing have been reported in vitro and in vivo studies 
as faster epithelialization with decreased inflammation 
and increased collagen and granulation tissue (27). In 
2011, Kan et al. (28) reported that they used laser thera-
py to prevent BRONJ after tooth extraction. Vescovi et 
al. reported that they prevented BRONJ after tooth ex-
traction in patients under BP treatment and in high-risk 
patients with a history of BRONJ, using a clinical proto-
col supported by Nd: YAG laser therapy in two separate 
studies (29,30). In our study, we used Nd: YAG laser for 
biostimulation in accordance with the protocol of Ves-
covi et al. (30).
Conclusions
Because the pathophysiology of MRONJ is not fully 
understood and has many risk factors, definitive pro-
tocols on prevention and treatment have not been es-
tablished yet. Personal risk assessment is required for 
the prevention and treatment of MRONJ. The surgical 
protocol presented in this study shows promising results 
for MRONJ protection after dentoalveolar surgery. Al-
though prospective studies with larger sample sizes are 
needed, we believe that our study will lead to better de-
signed future studies.
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